Jiyi Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jiyi Xu has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Congjie Xu
Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University , Haikou , P.R. China
2 shared publications- Hui Liang
Department of Neurology Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Hainan Clinical Medical Center, Hainan Academician Team Innovation Center Haikou People's Republic of China
2 shared publications - Hui Liang
Department of Neurology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Hainan Clinical Medical Center, Hainan Academician Team Innovation Center, Haikou, China
2 shared publications - Jing Du
The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, 5 Ankang Lane, Dewai Avenue, Xicheng District, Beijing 100088 China; Advanced lnnovation Center for Human Brain Protection, Capital Medical University, 10 Xi tou tiao, You An Men Wai, Fengtai District, Beijing 100069 China
2 shared publications - Lei Li
The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, 5 Ankang Lane, Dewai Avenue, Xicheng District, Beijing 100088 China; Advanced lnnovation Center for Human Brain Protection, Capital Medical University, 10 Xi tou tiao, You An Men Wai, Fengtai District, Beijing 100069 China
2 shared publications - Tianyi Wang
The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, 5 Ankang Lane, Dewai Avenue, Xicheng District, Beijing 100088 China; Advanced lnnovation Center for Human Brain Protection, Capital Medical University, 10 Xi tou tiao, You An Men Wai, Fengtai District, Beijing 100069 China
2 shared publications
Latest Publications
- 27 February 2026
- Published by Elsevier in Neuroscience Letters
- Vol. 877, 138569
Proteomic profiling of the prefrontal cortex reveals Dysregulated Mitochondria-Metabolism-Synapse axis in a chronic Stress-Induced mouse model of depression
- 27 February 2026
- Published by Elsevier in Neuroscience Letters
- Vol. 877, 138569
Proteomic profiling of the prefrontal cortex reveals Dysregulated Mitochondria-Metabolism-Synapse axis in a chronic Stress-Induced mouse model of depression
- 23 December 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (12) , e214465
Video NeuroImage: Stereotypic Motor Behaviors in a Patient With Pantothenate Kinase–Associated Neurodegeneration
- 23 December 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (12) , e214465
Video NeuroImage: Stereotypic Motor Behaviors in a Patient With Pantothenate Kinase–Associated Neurodegeneration
- 31 March 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 62 (8) , 9817-9828
The Role of Mitochondrial Dysfunction-Mediated Changes in Immune Cytokine Expression in the Pathophysiology and Treatment of Major Depressive Disorder
Recent studies have demonstrated an association between major depressive disorder (MDD) and both mitochondrial dysfunction and alterations in pro-inflammatory cytokine expression, suggesting that such changes may be key drivers of MDD pathogenesis. Mechanistically, changes in mitochondrial function are related to endoplasmic reticulum stress, reactive oxygen species production, oxidative phosphorylation, apoptosis, and disrupted calcium ion homeostasis, all of which trigger the activation of signaling cascades that affect the expression of pro-inflammatory cytokines, including tumor necrosis factor alpha, interleukin 1, interleukin 6, and interferons. Certain factors present in the gut microbiota ecosystem can influence communication between microorganisms and the brain through the neuroendocrine, immune, and autonomic nervous systems, thereby altering mitochondrial function and cytokine production. This review article explores the means through which mitochondria regulate immune cytokine expression and the role of mitochondrial dysfunction in the pathogenesis and treatment of MDD to provide new perspectives for the diagnosis of this disease and the development of novel therapeutic interventions with greater efficacy and improved safety profiles.
- 31 March 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 62 (8) , 9817-9828
The Role of Mitochondrial Dysfunction-Mediated Changes in Immune Cytokine Expression in the Pathophysiology and Treatment of Major Depressive Disorder
Recent studies have demonstrated an association between major depressive disorder (MDD) and both mitochondrial dysfunction and alterations in pro-inflammatory cytokine expression, suggesting that such changes may be key drivers of MDD pathogenesis. Mechanistically, changes in mitochondrial function are related to endoplasmic reticulum stress, reactive oxygen species production, oxidative phosphorylation, apoptosis, and disrupted calcium ion homeostasis, all of which trigger the activation of signaling cascades that affect the expression of pro-inflammatory cytokines, including tumor necrosis factor alpha, interleukin 1, interleukin 6, and interferons. Certain factors present in the gut microbiota ecosystem can influence communication between microorganisms and the brain through the neuroendocrine, immune, and autonomic nervous systems, thereby altering mitochondrial function and cytokine production. This review article explores the means through which mitochondria regulate immune cytokine expression and the role of mitochondrial dysfunction in the pathogenesis and treatment of MDD to provide new perspectives for the diagnosis of this disease and the development of novel therapeutic interventions with greater efficacy and improved safety profiles.
- 6 March 2025
- Published by Elsevier in Neuroscience Letters
- Vol. 852, 138184
1-Epilupinine enhances cognition and reduces inflammation in scopolamine-induced dementia model mice
- 6 March 2025
- Published by Elsevier in Neuroscience Letters
- Vol. 852, 138184
1-Epilupinine enhances cognition and reduces inflammation in scopolamine-induced dementia model mice
- Open Access
- 21 June 2023
- Published by Hong Kong Academy of Medicine Press in Hong Kong Medical Journal
- Vol. 29 (3) , 259-261
Uhthoff’s phenomenon as the initial symptom in neuromyelitis optica spectrum disorders: a case report
Hong Kong Med J 2023 Jun;29(3):259–61 https://doi.org/10.12809/hkmj219977 © Hong Kong Academy of Medicine.
- 21 June 2023
- Published by Hong Kong Academy of Medicine Press in Hong Kong Medical Journal
- Vol. 29 (3) , 259-261
Open AccessUhthoff’s phenomenon as the initial symptom in neuromyelitis optica spectrum disorders: a case report
Hong Kong Med J 2023 Jun;29(3):259–61 https://doi.org/10.12809/hkmj219977 © Hong Kong Academy of Medicine.
- Open Access
- 3 May 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 208 (3) , 372-379
Genetic correlation between thyroid hormones and Parkinson’s disease
Parkinson’s disease (PD) was reported to be connected with thyroid diseases clinically, which might be a critical clew to immune pathogenesis of PD. However, there was no further research to study the pathogenesis correlation between PD and thyroid diseases. In this study, except for investigating the difference in thyroid hormone between PD and the control group, we explored genetic correlation between thyroid and PD. We tried to find their shared molecular pathway by analyzing the effect of PD risk genes on thyroid function. Interestingly, most of those 12 meaningful SNPs we found could affect PD and thyroid function through immune mechanism, which is consistent with our original conjecture and provides significant evidence for the immune pathogenesis of PD.
- 3 May 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 208 (3) , 372-379
Open AccessGenetic correlation between thyroid hormones and Parkinson’s disease
Parkinson’s disease (PD) was reported to be connected with thyroid diseases clinically, which might be a critical clew to immune pathogenesis of PD. However, there was no further research to study the pathogenesis correlation between PD and thyroid diseases. In this study, except for investigating the difference in thyroid hormone between PD and the control group, we explored genetic correlation between thyroid and PD. We tried to find their shared molecular pathway by analyzing the effect of PD risk genes on thyroid function. Interestingly, most of those 12 meaningful SNPs we found could affect PD and thyroid function through immune mechanism, which is consistent with our original conjecture and provides significant evidence for the immune pathogenesis of PD.
- Open Access
- 2 May 2022
- Published by Springer Nature in BMC Neurology
- Vol. 22 (1) , 1-7
Cerebral venous sinus thrombosis and dural arteriovenous fistula associated with protein S deficiency: a case series study
Objective: To describe the characteristics of patients with cerebral venous sinus thrombosis (CVST) and dural arteriovenous fistula (AVF) associated with protein S (PS) deficiency. Methods: We conducted a search of medical records in Hainan General Hospital from January 2000 to December 2020 for coexistence of CVST and dural AVF associated with PS deficiency and searched PubMed、Embase and Chinese biomedical databases (CBM) for all literature describing CVST and dural AVF with PS. We analyzed clinical characteristics, location, sequence of CVST and dural AVF, level of PS, therapeutic methods and prognosis. Results: We presented 1 patient in our hospital’s database combined CVST and dural AVF associated with PS, plus 5 cases reported in literature. The most common symptoms were headache, generalized seizure, disturbance of consciousness. The most frequent location of CVST was at internal cerebral vein, while transverse sinus, sigmoid sinus, parietal region in dural AVF. Two patients developed dural AVF several months or years after CVST. Clinical characteristics and level of PS were summarized. Conclusion: These findings alert physicians to consider PS deficiency in patients who suffer from CVST, especially those combined with dural AVF.
- 2 May 2022
- Published by Springer Nature in BMC Neurology
- Vol. 22 (1) , 1-7
Open AccessCerebral venous sinus thrombosis and dural arteriovenous fistula associated with protein S deficiency: a case series study
Objective: To describe the characteristics of patients with cerebral venous sinus thrombosis (CVST) and dural arteriovenous fistula (AVF) associated with protein S (PS) deficiency. Methods: We conducted a search of medical records in Hainan General Hospital from January 2000 to December 2020 for coexistence of CVST and dural AVF associated with PS deficiency and searched PubMed、Embase and Chinese biomedical databases (CBM) for all literature describing CVST and dural AVF with PS. We analyzed clinical characteristics, location, sequence of CVST and dural AVF, level of PS, therapeutic methods and prognosis. Results: We presented 1 patient in our hospital’s database combined CVST and dural AVF associated with PS, plus 5 cases reported in literature. The most common symptoms were headache, generalized seizure, disturbance of consciousness. The most frequent location of CVST was at internal cerebral vein, while transverse sinus, sigmoid sinus, parietal region in dural AVF. Two patients developed dural AVF several months or years after CVST. Clinical characteristics and level of PS were summarized. Conclusion: These findings alert physicians to consider PS deficiency in patients who suffer from CVST, especially those combined with dural AVF.
- 13 April 2022
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 78 (7) , 1203-1204
Case report: cold medicines cause neuroleptic malignant-like syndrome in a patient with Parkinson’s disease
- 13 April 2022
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 78 (7) , 1203-1204
Case report: cold medicines cause neuroleptic malignant-like syndrome in a patient with Parkinson’s disease
- RetractedOpen Access
- 6 September 2021
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-8
Repetitive Transcranial Magnetic Stimulation Improves Neuropathy and Oxidative Stress Levels in Rats with Experimental Cerebral Infarction through the Nrf2 Signaling Pathway
Ischemic stroke poses a serious threat to human health. Its high morbidity, disability, and lethality rates have led to it being a research hotspot. Cerebral ischemia reperfusion injury is a difficult point in the treatment of ischemic stroke. In recent years, studies have shown that repeated transcranial magnetic stimulation (rTMS) can enhance cerebral ischemic tolerance and have a significant protective effect on reperfusion injury after ischemia, but its specific mechanism is unknown. The Nrf2/pathway plays a vital role in ischemia-reperfusion injury in the body environment. Therefore, in this experiment, the middle cerebral artery occlusion (MCAO) reperfusion model of SD rats was made to simulate the occurrence of experimental cerebral infarction by the suture method. After treatment with rTMS, it was studied whether it can regulate the expression of Nrf2 and HO-1, affect the content of MDA and SOD activity, and then activate the Nrf2 pathway to exert its brain protection. The results showed that after MCAO reperfusion, the neurological deficit score of rats increased, and the time to remove the bilateral stickers and the time to cross the balance beam increased, suggesting the successful establishment of the experimental cerebral infarction model. Detecting the brain tissue of experimental cerebral infarction rats found that the expression of Nrf2 and HO-1 decreased, the content of MDA increased, and the activity of SOD decreased. After rTMS treatment, the neuromotor function of experimental cerebral infarction rats improved, the expression of Nrf2 and HO-1 in the brain tissue gradually increased, the content of MDA decreased, and the activity of SOD increased. It indicates that the expression of Nrf2 and HO-1 in experimental cerebral infarction rats is reduced. After treatment with rTMS, it can improve the neuromotor function damage of the rats and reduce the level of oxidative stress. The mechanism may be through promoting the activation of the Nrf2 signaling pathway, acting on the expression of antioxidant proteins, such as HO-1 and SOD1, reducing oxidative stress damage, and playing a protective effect on brain tissue.
- 6 September 2021
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-8
RetractedOpen AccessRepetitive Transcranial Magnetic Stimulation Improves Neuropathy and Oxidative Stress Levels in Rats with Experimental Cerebral Infarction through the Nrf2 Signaling Pathway
Ischemic stroke poses a serious threat to human health. Its high morbidity, disability, and lethality rates have led to it being a research hotspot. Cerebral ischemia reperfusion injury is a difficult point in the treatment of ischemic stroke. In recent years, studies have shown that repeated transcranial magnetic stimulation (rTMS) can enhance cerebral ischemic tolerance and have a significant protective effect on reperfusion injury after ischemia, but its specific mechanism is unknown. The Nrf2/pathway plays a vital role in ischemia-reperfusion injury in the body environment. Therefore, in this experiment, the middle cerebral artery occlusion (MCAO) reperfusion model of SD rats was made to simulate the occurrence of experimental cerebral infarction by the suture method. After treatment with rTMS, it was studied whether it can regulate the expression of Nrf2 and HO-1, affect the content of MDA and SOD activity, and then activate the Nrf2 pathway to exert its brain protection. The results showed that after MCAO reperfusion, the neurological deficit score of rats increased, and the time to remove the bilateral stickers and the time to cross the balance beam increased, suggesting the successful establishment of the experimental cerebral infarction model. Detecting the brain tissue of experimental cerebral infarction rats found that the expression of Nrf2 and HO-1 decreased, the content of MDA increased, and the activity of SOD decreased. After rTMS treatment, the neuromotor function of experimental cerebral infarction rats improved, the expression of Nrf2 and HO-1 in the brain tissue gradually increased, the content of MDA decreased, and the activity of SOD increased. It indicates that the expression of Nrf2 and HO-1 in experimental cerebral infarction rats is reduced. After treatment with rTMS, it can improve the neuromotor function damage of the rats and reduce the level of oxidative stress. The mechanism may be through promoting the activation of the Nrf2 signaling pathway, acting on the expression of antioxidant proteins, such as HO-1 and SOD1, reducing oxidative stress damage, and playing a protective effect on brain tissue.